Comparison Overview

Catalent

VS

Johnson & Johnson Innovative Medicine

Catalent

101 E Kennedy Blvd, Tampa, Florida, US, 33602
Last Update: 2026-01-24
Between 750 and 799

Championing the missions that matter™. Catalent, Inc. is a leading global contract development and manufacturing organization (CDMO) and trusted partner to pharma, biotech, and consumer health companies worldwide. We put patients first in everything we do, helping people live better and healthier lives through every product we help develop, manufacture and deliver. With over 1,000 active development programs at any given time, we launch over 100 new products and line extensions annually. Catalent has supported half of all FDA approvals over the past decade, and our teams working at over 40 global sites help us produce over 60 billion doses every year. Our strength lies in our people: teams across our more than 40 sites and thousands of passionate scientists and technicians who bring expertise in development sciences, delivery technologies, and multi-modality manufacturing. What unites us is our commitment to championing our partners’ missions as our own, anticipating customer needs, solving complex challenges and ultimately making a difference in the lives of patients across the globe. At Catalent, you will be able to directly have an impact, solving problems and ensuring excellence for our customers. Our focus on delivering meaningful outcomes alongside our customers means your work directly impacts millions of people around the world. Join us in championing the missions that matter. Catalent is headquartered in Tampa, Florida, with over 40 global sites. Visit www.catalent.com to learn more.

NAICS: 3254
NAICS Definition: Pharmaceutical and Medicine Manufacturing
Employees: 12,729
Subsidiaries: 1
12-month incidents
0
Known data breaches
0
Attack type number
0

Johnson & Johnson Innovative Medicine

None
Last Update: 2026-01-18

At Johnson & Johnson Innovative Medicine, we innovate with purpose, to lead where medicine is going. The experiences of patients around the world inform and inspire our science-based innovations, which continue to change and save lives. Applying rigorous science with compassion, we confidently address the most complex diseases of our time and develop the potential medicines of tomorrow. We are continuously working to develop treatments, aspiring to find cures, pioneering the path from lab to life, and championing patients every step of the way. https://bit.ly/3reuMvK

NAICS: 3254
NAICS Definition: Pharmaceutical and Medicine Manufacturing
Employees: 37,729
Subsidiaries: 10
12-month incidents
0
Known data breaches
0
Attack type number
0

Compliance Badges Comparison

Security & Compliance Standards Overview

https://images.rankiteo.com/companyimages/catalent.jpeg
Catalent
ISO 27001
ISO 27001 certification not verified
Not verified
SOC2 Type 1
SOC2 Type 1 certification not verified
Not verified
SOC2 Type 2
SOC2 Type 2 certification not verified
Not verified
GDPR
GDPR certification not verified
Not verified
PCI DSS
PCI DSS certification not verified
Not verified
HIPAA
HIPAA certification not verified
Not verified
https://images.rankiteo.com/companyimages/jnjinnovativemedicine.jpeg
Johnson & Johnson Innovative Medicine
ISO 27001
ISO 27001 certification not verified
Not verified
SOC2 Type 1
SOC2 Type 1 certification not verified
Not verified
SOC2 Type 2
SOC2 Type 2 certification not verified
Not verified
GDPR
GDPR certification not verified
Not verified
PCI DSS
PCI DSS certification not verified
Not verified
HIPAA
HIPAA certification not verified
Not verified
Compliance Summary
Catalent
100%
Compliance Rate
0/4 Standards Verified
Johnson & Johnson Innovative Medicine
0%
Compliance Rate
0/4 Standards Verified

Benchmark & Cyber Underwriting Signals

Incidents vs Pharmaceutical Manufacturing Industry Average (This Year)

No incidents recorded for Catalent in 2026.

Incidents vs Pharmaceutical Manufacturing Industry Average (This Year)

No incidents recorded for Johnson & Johnson Innovative Medicine in 2026.

Incident History — Catalent (X = Date, Y = Severity)

Catalent cyber incidents detection timeline including parent company and subsidiaries

Incident History — Johnson & Johnson Innovative Medicine (X = Date, Y = Severity)

Johnson & Johnson Innovative Medicine cyber incidents detection timeline including parent company and subsidiaries

Notable Incidents

Last 3 Security & Risk Events by Company

https://images.rankiteo.com/companyimages/catalent.jpeg
Catalent
Incidents

No Incident

https://images.rankiteo.com/companyimages/jnjinnovativemedicine.jpeg
Johnson & Johnson Innovative Medicine
Incidents

No Incident

FAQ

Johnson & Johnson Innovative Medicine company demonstrates a stronger AI Cybersecurity Score compared to Catalent company, reflecting its advanced cybersecurity posture governance and monitoring frameworks.

Historically, Johnson & Johnson Innovative Medicine company has disclosed a higher number of cyber incidents compared to Catalent company.

In the current year, Johnson & Johnson Innovative Medicine company and Catalent company have not reported any cyber incidents.

Neither Johnson & Johnson Innovative Medicine company nor Catalent company has reported experiencing a ransomware attack publicly.

Neither Johnson & Johnson Innovative Medicine company nor Catalent company has reported experiencing a data breach publicly.

Neither Johnson & Johnson Innovative Medicine company nor Catalent company has reported experiencing targeted cyberattacks publicly.

Neither Catalent company nor Johnson & Johnson Innovative Medicine company has reported experiencing or disclosing vulnerabilities publicly.

Neither Catalent nor Johnson & Johnson Innovative Medicine holds any compliance certifications.

Neither company holds any compliance certifications.

Johnson & Johnson Innovative Medicine company has more subsidiaries worldwide compared to Catalent company.

Johnson & Johnson Innovative Medicine company employs more people globally than Catalent company, reflecting its scale as a Pharmaceutical Manufacturing.

Neither Catalent nor Johnson & Johnson Innovative Medicine holds SOC 2 Type 1 certification.

Neither Catalent nor Johnson & Johnson Innovative Medicine holds SOC 2 Type 2 certification.

Neither Catalent nor Johnson & Johnson Innovative Medicine holds ISO 27001 certification.

Neither Catalent nor Johnson & Johnson Innovative Medicine holds PCI DSS certification.

Neither Catalent nor Johnson & Johnson Innovative Medicine holds HIPAA certification.

Neither Catalent nor Johnson & Johnson Innovative Medicine holds GDPR certification.

Latest Global CVEs (Not Company-Specific)

Description

Typemill is a flat-file, Markdown-based CMS designed for informational documentation websites. A reflected Cross-Site Scripting (XSS) exists in the login error view template `login.twig` of versions 2.19.1 and below. The `username` value can be echoed back without proper contextual encoding when authentication fails. An attacker can execute script in the login page context. This issue has been fixed in version 2.19.2.

Risk Information
cvss3
Base: 5.4
Severity: LOW
CVSS:3.1/AV:N/AC:L/PR:N/UI:R/S:U/C:L/I:L/A:N
Description

A DOM-based Cross-Site Scripting (XSS) vulnerability exists in the DomainCheckerApp class within domain/script.js of Sourcecodester Domain Availability Checker v1.0. The vulnerability occurs because the application improperly handles user-supplied data in the createResultElement method by using the unsafe innerHTML property to render domain search results.

Description

A Remote Code Execution (RCE) vulnerability exists in Sourcecodester Modern Image Gallery App v1.0 within the gallery/upload.php component. The application fails to properly validate uploaded file contents. Additionally, the application preserves the user-supplied file extension during the save process. This allows an unauthenticated attacker to upload arbitrary PHP code by spoofing the MIME type as an image, leading to full system compromise.

Description

A UNIX symbolic link following issue in the jailer component in Firecracker version v1.13.1 and earlier and 1.14.0 on Linux may allow a local host user with write access to the pre-created jailer directories to overwrite arbitrary host files via a symlink attack during the initialization copy at jailer startup, if the jailer is executed with root privileges. To mitigate this issue, users should upgrade to version v1.13.2 or 1.14.1 or above.

Risk Information
cvss3
Base: 6.0
Severity: LOW
CVSS:3.1/AV:L/AC:L/PR:H/UI:N/S:U/C:N/I:H/A:H
cvss4
Base: 6.0
Severity: LOW
CVSS:4.0/AV:L/AC:L/AT:N/PR:H/UI:N/VC:N/VI:N/VA:N/SC:N/SI:H/SA:H/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X
Description

An information disclosure vulnerability exists in the /srvs/membersrv/getCashiers endpoint of the Aptsys gemscms backend platform thru 2025-05-28. This unauthenticated endpoint returns a list of cashier accounts, including names, email addresses, usernames, and passwords hashed using MD5. As MD5 is a broken cryptographic function, the hashes can be easily reversed using public tools, exposing user credentials in plaintext. This allows remote attackers to perform unauthorized logins and potentially gain access to sensitive POS operations or backend functions.